Ascopiave (BIT:ASC) Might Be Having Difficulty Using Its Capital Effectively

Did you know there are some financial metrics that can provide clues of a potential multi-bagger? One common approach is to try and find a company with returns on capital employed (ROCE) that are increasing, in conjunction with a growing amount of capital employed. This shows us that it's a compounding machine, able to continually reinvest its earnings back into the business and generate higher returns. However, after briefly looking over the numbers, we don't think Ascopiave (BIT:ASC) has the makings of a multi-bagger going forward, but let's have a look at why that may be.

Advertisement

What is Return On Capital Employed (ROCE)?

If you haven't worked with ROCE before, it measures the 'return' (pre-tax profit) a company generates from capital employed in its business. To calculate this metric for Ascopiave, this is the formula:

Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities)

0.028 = €31m ÷ (€1.4b - €302m) (Based on the trailing twelve months to March 2021).

So, Ascopiave has an ROCE of 2.8%. Ultimately, that's a low return and it under-performs the Gas Utilities industry average of 6.5%.

See our latest analysis for Ascopiave

roce
BIT:ASC Return on Capital Employed July 20th 2021

In the above chart we have measured Ascopiave's prior ROCE against its prior performance, but the future is arguably more important. If you'd like, you can check out the forecasts from the analysts covering Ascopiave here for free.

What Can We Tell From Ascopiave's ROCE Trend?

On the surface, the trend of ROCE at Ascopiave doesn't inspire confidence. To be more specific, ROCE has fallen from 11% over the last five years. Although, given both revenue and the amount of assets employed in the business have increased, it could suggest the company is investing in growth, and the extra capital has led to a short-term reduction in ROCE. If these investments prove successful, this can bode very well for long term stock performance.

On a related note, Ascopiave has decreased its current liabilities to 22% of total assets. So we could link some of this to the decrease in ROCE. What's more, this can reduce some aspects of risk to the business because now the company's suppliers or short-term creditors are funding less of its operations. Some would claim this reduces the business' efficiency at generating ROCE since it is now funding more of the operations with its own money.

Our Take On Ascopiave's ROCE

Even though returns on capital have fallen in the short term, we find it promising that revenue and capital employed have both increased for Ascopiave. And the stock has followed suit returning a meaningful 64% to shareholders over the last five years. So should these growth trends continue, we'd be optimistic on the stock going forward.

One more thing to note, we've identified 1 warning sign with Ascopiave and understanding this should be part of your investment process.

If you want to search for solid companies with great earnings, check out this free list of companies with good balance sheets and impressive returns on equity.

When trading Ascopiave or any other investment, use the platform considered by many to be the Professional's Gateway to the Worlds Market, Interactive Brokers. You get the lowest-cost* trading on stocks, options, futures, forex, bonds and funds worldwide from a single integrated account. Promoted


New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
*Interactive Brokers Rated Lowest Cost Broker by StockBrokers.com Annual Online Review 2020


Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

MI
mitchell_lawler
mitchell_lawler

Moderna nearly tripled overnight, and every other mRNA stock jumped with it. I think that could be a trap.

Moderna nearly tripled overnight, and every other mRNA stock jumped with it. I think that could be a trap. cover
98
PR
pri_dlp7z

Happy for the melanoma patients. It is no surprise that other companies moved up too. It's the optionality getting priced in.

QU
Quantanium

There’s a 60% to 85% probability of the vaccine being approved based on historical drug development data. Could be a lot of scrutiny by the FDA due to the novel platform used.

Market might be getting a little ahead of itself here.

About BIT:ASC

Ascopiave

Engages in the distribution of natural gas in Italy.

Slight risk second-rate dividend payer.

Similar Companies

Advertisement

Weekly Picks

RI
Rick_Orford
FJET logo
Rick_Orford on Starfighters Space ·

The 1960s Fighter Jet That Could Crack Open a $20 Billion Satellite Market

Fair Value:US$520.6% undervalued
53 users have followed this narrative
2 users have commented on this narrative
7 users have liked this narrative
JO
John_Eric
MELI logo
John_Eric on MercadoLibre ·

MercadoLibre and the Spreadsheet Trick That Decides Everything

Fair Value:US$7.31k73.9% undervalued
99 users have followed this narrative
2 users have commented on this narrative
15 users have liked this narrative
RC
PYPL logo
rcb9 on PayPal Holdings ·

Ten Percent More Volume, One Percent More Transaction Margin

Fair Value:US$70.8913.6% undervalued
12 users have followed this narrative
1 users have commented on this narrative
5 users have liked this narrative
HE
HedgeY
MU logo
HedgeY on Micron Technology ·

Micron - The Memory Bottleneck Behind the AI Supercycle

Fair Value:US$1.25k25.0% undervalued
35 users have followed this narrative
0 users have commented on this narrative
11 users have liked this narrative

Updated Narratives

RO
RockeTeller
WRLG logo
RockeTeller on West Red Lake Gold Mines ·

This Junior Gold Mine Just Hit Commercial Production, 120k oz Roadmap at $7,000 Gold

Fair Value:CA$4.3681.4% undervalued
27 users have followed this narrative
8 users have commented on this narrative
0 users have liked this narrative
AS
AstrisCorporateAdvisory
9436 logo
AstrisCorporateAdvisory on Okinawa Cellular Telephone ·

Mobile strategy pays off as churn falls

Fair Value:JP¥3.26k23.3% overvalued
2 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
AS
AstrisCorporateAdvisory
3636 logo
AstrisCorporateAdvisory on Mitsubishi Research Institute ·

Exceptionally strong Q1 results, while FY guidance intact

Fair Value:JP¥4.2k18.8% overvalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

OS
oscargarcia
NVDA logo
oscargarcia on NVIDIA ·

The company that went from selling GPUs to gamers to becoming the AI arms dealer of the 21st century.

Fair Value:US$28022.3% undervalued
329 users have followed this narrative
9 users have commented on this narrative
16 users have liked this narrative
CU
MSFT logo
CubanEros on Microsoft ·

A wonderful business at reasonable price.

Fair Value:US$419.9115.3% overvalued
184 users have followed this narrative
0 users have commented on this narrative
9 users have liked this narrative
KI
AMZN logo
KiwiInvest on Amazon.com ·

Amazon's high growth, high tech segments propel its profits, while traditional segments plod along

Fair Value:US$475.0944.0% undervalued
209 users have followed this narrative
1 users have commented on this narrative
8 users have liked this narrative